• Vaccine Name: Actinobacillus pleuropneumoniae ureC and apxIIA double mutant deletion vaccine
• Target Pathogen: Actinobacillus pleuropneumoniae
• Target Disease: porcine pleuropneumonia
• Type: Live, attenuated vaccine
• Status: Research
• apxIIA gene engineering:
  • Type: Gene mutation
  • Description:
  • Detailed Gene Information: Click Here.
• ureC gene engineering:
  • Type: Gene mutation
  • Description:
  • Detailed Gene Information: Click Here.
• Preparation: To construct the A. pleuropneumoniae serotype 2 isogenic mutant, 12 clinical isolates were tested initially with respect to their amenability to genetic manipulation via conjugation and cointegration of pBMKUΔ1 (Tonpitak et al., 2002).
• Immunization Route: aerosol immunization

Pig Response

• Persistence: In all pigs, an immune response could be detected in the detergent extract enzyme-linked immunosorbent assay (ELISA), and only in the wild-type group six of seven pigs showed elevated levels (>10 ELISA units [EU]) in the ApxIIA ELISA 3 weeks after challenge. These results showed that the A. pleuropneumoniae double-mutant strain is highly attenuated and that the group infected with the mutant strain can be discriminated from the wild-type-infected group based on the ApxIIA ELISA (Tonpitak et al., 2002).
• Efficacy: A single aerosol application of the attenuated double mutant resulted in protection from clinical disease comparable to that obtained with two applications by using a conventional bacterin vaccine. In addition, immunized pigs were protected significantly from colonization of the lungs (Tonpitak et al., 2002).